Candel Therapeutics Announces Participation in Key Investor Events
Engagement in Investor Conferences
Candel Therapeutics, Inc. (NASDAQ: CADL) has recently announced its participation in important investor conferences where its President and CEO, Paul Peter Tak, will be engaging with potential and current investors. This provides a significant opportunity for stakeholders to gain insights into the company’s innovative approach to cancer treatment.
Details of Upcoming Conferences
The following are the specifics of the investor conferences where Candel Therapeutics will be present:
Citi's Biopharma Conference
This conference will take place on September 3, 2025, at 9:00 AM ET. It is an excellent platform for Candel’s leadership to discuss the progress of their clinical programs. Investors can look forward to a dynamic presentation and a fireside chat, offering a closer look at the company’s strategy and goals.
Cantor Global Healthcare Conference
On September 4, 2025, starting at 8:00 AM ET, Candel Therapeutics will also participate in the Cantor Global Healthcare Conference. This event is an essential venue for discussing the latest advancements in cancer therapies and the company’s unique solutions.
H.C. Wainwright Global Investment Conference
The following day, on September 5, 2025, Candel will be presenting at the H.C. Wainwright 27th Annual Global Investment Conference at 7:00 AM ET. The presentations across these conferences are tailored to provide valuable perspectives on Candel's development pipeline and future prospects in the biopharmaceutical sector.
Access to Live Webcasts
For those who cannot attend the conferences, Candel Therapeutics will provide live webcasts of their presentations. Investors can readily access these webcasts by visiting the Investors section on the company's website under the Events and Presentations tab. This commitment to transparency and communication is crucial for building trust and fostering stakeholder engagement.
About Candel Therapeutics
Candel Therapeutics is leading the charge in cancer treatment through innovative multimodal biological immunotherapies. These therapies are designed to harness and enhance the body's immune response, targeting tumors more effectively. The company's lead product candidate, CAN-2409, demonstrates promising potential in clinical-stage trials, particularly for cancers that are traditionally difficult to treat such as non-small cell lung cancer and localized prostate cancer.
Recent Clinical Trials
Candel has recently completed a phase 2a clinical trial for CAN-2409, yielding encouraging results for patients suffering from non-small cell lung cancer and pancreatic ductal adenocarcinoma. Furthermore, the Food and Drug Administration (FDA) has recognized CAN-2409 with several designations aimed at speeding the development of this essential treatment within specific patient populations.
Innovative Platforms for Cancer Therapy
Alongside CAN-2409, Candel is advancing another candidate, CAN-3110, which is under investigation in a phase 1b clinical trial targeted at treating recurrent high-grade glioma. These contributions are complemented by Candel's enLIGHTEN™ Discovery Platform, demonstrating a commitment to harnessing advanced research methodologies and human biology to discover innovative therapies.
Contact Information
For any inquiries regarding Candel’s investor relations, contact:
Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.
Email: tjenkins@candeltx.com
Frequently Asked Questions
What is the focus of Candel Therapeutics?
Candel Therapeutics focuses on developing multimodal biological immunotherapies to enhance cancer treatment.
What are the key upcoming conferences for Candel?
Candel will participate in Citi's Biopharma Conference, Cantor Global Healthcare Conference, and H.C. Wainwright Global Investment Conference.
How does Candel communicate with its investors?
Candel provides live webcasts of its presentations during conferences and maintains an updated Investors section on its website.
What is CAN-2409?
CAN-2409 is Candel's lead product candidate, currently investigated in clinical trials for its effectiveness in fighting cancer.
Who should investors contact at Candel Therapeutics?
Investors can contact Theodore Jenkins, the Vice President of Investor Relations, for inquiries.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.